Key Takeaways
- Revenue down, but mix drove margins up: Revenue fell to INR 652.6 crores from INR 789 crores YoY, but the quarter was dominated by high-margin development services, pushing CDMO EBITDA margin to 25.3% (vs 19% in Q2 FY25).
- H2 promises a commercial rebound: H1 CDMO revenue was flat, but management expects a much stronger H2 as commercial shipments land in Q3 and Q4, supporting full-year revenue growth of 8–10%.
- The French facility is now a real, certified asset: A GMP certificate has unlocked late-phase RFPs, and the site is expected to surpass EBITDA breakeven in FY27, removing a drag on consolidated margins.
- Bavla’s ramp-up is a FY27 story, not an FY26 one: Revenue recognition from new contracts starts next financial year; current utilization is only 20–25%, but management expects exponential growth toward an INR 800 crores target over three years.
- What to watch next quarter: Whether the promised H2 commercial shipment surge materializes, the pace of Bavla contract signings, and any concrete numbers from the Celonic collaboration.
Revenue & Margin Drivers
- Q2 FY25 base effect explains the headline decline: Q2 FY25 had a huge deferment of orders from Q1, making that quarter exceptionally high versus the run rate, so the YoY drop is not a like-for-like comparison.
- Development mix juiced margins: Most Q2 revenue came from Phase 3 work and supplies to a Japanese innovator for an ADC, which carry substantially higher margins and lower material consumption. COGS was lower mainly because of the high contribution from this Phase 3 molecule, where material cost is quite low.
- H2 shift toward commercial: H1 CDMO revenue was flat versus H1 FY25, but H2 is expected to be much stronger as commercial shipments, which carry lower margins than late-phase development but higher volumes, come in Q3 and Q4. For the full year, COGS is expected to be a bit lower than last year, but higher than Q2.
- Marketable Molecules grew 85% in Q2: Dominated by cholesterol and vitamin D analogue business, which is on target or may exceed the full-year target. However, segment margin fell 170 bps to 14% because the Naroda/Quats business had lower margins, while the vitamin D/cholesterol business did ~18%.
- Finance cost optics vs cash: Finance cost appears higher than actual cash outflow due to translation impact on Swiss borrowings. Interest costs are now declining: Swiss entity borrowings reduced to ~10 crore, and SARON at 0% means only the spread is paid. Indian debt remains high and is targeted for retirement.
- Tax provision gave a one-time lift: Tax expense had a positive impact from provision for capital tax assets at locations expected to turn profitable over the next 3–5 years.
Harshil Dalal: "We do expect that the revenue should grow exponentially from here on."
French Facility: From Drag to Driver
- GMP certificate changed the conversation: The facility received its GMP certificate and is now getting more RFPs, including for late-phase projects that could go commercial, not just early-phase work. Interest from customers post-certification is described as "huge."
- End-to-end ADC offering is the magnet: The combination of antibody supply from the Celonic collaboration, conjugation, payload, linker, and form-fill-finish at the French site creates a one-stop shop that is driving customer interest.
- Profitability inflection in FY27: The facility is expected to surpass its EBITDA breakeven of EUR 18 million in the next financial year; the current year still expects EBITDA losses. Peak revenue of EUR 45 million is achievable, with full capacity utilization expected in close to about four years. A third line can be set up in future if needed.
- No doubts on the ramp: Management expressed high confidence in ramping the facility "quite significantly going forward," though no specific quarterly trajectory was given.
Harshil Dalal: "So, we have no doubts of ramping up the French facility quite significantly going forward."
Bavla: The FY27 Growth Engine
- Revenue recognition starts next year: New contracts have been signed, including one for an Italian customer, and visits for potential Japanese customers are scheduled, but revenue recognition is expected to begin only from FY27. Current-year Bavla revenue is similar to last year at ~INR 250 crores.
- Utilization is just 20–25% today: The site has significant headroom, and management expects QoQ revenue increases from FY27 onward, targeting INR 800 crores over the next three years.
- Integration is unlocking demand: A unified business development organization now covers both India and Switzerland, and closer integration is driving customer interest, with RSQs increasing. The site will also start targeting Phase 3 molecules or positions as a second supplier, for example as an alternative to Chinese suppliers.
- Working capital is the near-term pinch: The largest blockage is in inventory because customers mandate keeping certain stock levels of APIs, semi-finished or finished, to avoid shortages impacting their product launches in new markets.
Harshil Dalal: "So progressively, what we will see in the next financial year is that QoQ, there should be an increase in the revenues coming out of the Bavla site. And in order to touch the INR 800 crores, the target is that we should be able to touch that over the next three years."
Strategic Partnerships & Pipeline
- Celonic collaboration closes the antibody gap: The partnership with Celonic, a small CDMO in antibody production and development, fills a gap in the antibody development offering. Management calls it a "win-win-win" because Carbogen Amcis gains access to Celonic's clients, Celonic gets access to Carbogen Amcis's clients, and the client gets a one-stop shop.
- No quick revenue from Celonic: A handful of customers are under discussion, but negotiations typically take 3–6 months for project understanding, sizing, and contractual details. Management expects an increase in revenue and profit but gave no specific number or timeline.
- Japanese client co-investment deepens: A second co-investment agreement was entered into in June 2025 with a Japanese customer for CHF 2.5 crore, entirely customer-funded, for expansion at Neuland and Aarau sites in Switzerland. The client is also investing in bigger quantities and capacities in Switzerland.
- 12 late-phase molecules, no commercialization timeline: Management declined to say how many of the 12 late-phase molecules will commercialize next year, calling it "anybody's guess right now" because it depends on customer pursuit and regulatory agencies.
- ADC molecule in late Phase 1/early Phase 2: A collaboration started ~12 years ago spans Manchester, Shanghai, Neuland, Swiss sites, and Bubendorf for the high-potent part, conjugation with a purchased antibody, then drug product formulation at Saint-Beauzire, France. It is a peptide derivative for an oncology/breast cancer indication.
Stephan Fritschi: "I call this as a win-win-win situation because Carbogen Amcis benefits and profits of this collaboration because we can get more clients, different clients, which come from Celonic. The same is the case for Celonic itself. They get our clients in collaboration. And last but not least, but most important is that the client gets the benefit of this new one-stop shop feature we can offer out of us."
Integration & Digital Transformation
- Sales and IT now unified: Since September 1, 2025, one sales organization under Francois Baduel covers all sales activities, eliminating duplication. Since November 3, 2025, IT activities have been combined under Sanjeev Jain for both Carbogen Amcis and Dishman Carbogen Amcis. Procurement is the next integration step being looked into.
- SAP S/4HANA migration underway: India has operated on SAP for 16 years; the Netherlands has been upgraded to S/4HANA. The fourth phase, the Swiss entity, should go live in the next 4–6 months, followed by replication in Manchester, Shanghai, and finally France. Total estimated cost is CHF 1.5 crore (~INR 150 crores).
- Common systems beyond ERP: The group is also looking at common systems for lab management software and other functions across the group as part of a broader digital transformation.
Balance Sheet & Capital Allocation
- Fundraise of INR 500–700 crores to retire Indian debt: The idea is to pay down India debt as quickly as possible to improve EBIT to PBT/PAT conversion and deploy interest savings into working capital for increased business at the Bavla site. Indian debt is roughly INR 700-odd crores.
- ROCE target of 25% over 4–5 years: Management stated this is an internal target and that they are "very much on track to achieve" it, citing an extremely strong pipeline for Bavla.
- CapEx guided at INR 200–210 crores for FY26: No heavy investment is needed for larger volume capacity because capacity has already been created in India; the focus is on utilizing Bavla capacity more efficiently, with some refurbishment expenditure possible but not significant.
- ADC conjugation capacity may expand in Switzerland: Interest may require an increase, but management would keep it in Switzerland because the quantities required are not large.
Harshil Dalal: "Our internal target is to get to the 25% ROCE margins over the next four years to five years. So, that is something which we are very much on track to achieve because we are looking at an extremely strong pipeline for Bavla."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth FY26 | Close to 8–10% total revenue growth for entire business | FY26 |
| EBITDA margin FY26 | Expect to reach ~20% (from guided 18–20%) based on H1 results and H2 expectations | FY26 |
| CDMO H2 mix shift | Second half much stronger than first half; more commercial share of revenue | H2 FY26 |
| French facility EBITDA breakeven | Surpass EUR 18 million EBITDA breakeven | FY27 |
| French facility full capacity | Reach full capacity utilization | Close to ~4 years |
| Bavla revenue target | Reach INR 800 crores | Over the next 3 years |
| CDMO revenue target | INR 3,000 crores (includes French facility, India, Bavla, Switzerland, Manchester, Shanghai) | FY27 |
| ROCE target | 25% | Over next 4–5 years |
| CapEx FY26 | Close to INR 200–210 crores | FY26 |
| Fundraise | INR 500–700 crores to retire Indian debt | No date given |
| SAP S/4HANA Swiss go-live | Fourth phase go-live | Next 4–6 months |
Key Metrics
| Metric | Q2 FY26 |
|---|---|
| Revenue | ₹652.6 cr, vs ₹789 cr in Q2 FY25 (exceptionally high due to Q1 deferment) |
| EBITDA | ₹149 cr, H1 FY26 at ₹289.5 cr, up 64.4% YoY |
| EBITDA margin | 22.8%, vs 13.4% in H1 FY25; H1 FY26 at 21.3% |
| Profit after tax | ₹65 cr, vs ₹33 cr in Q2 FY25; H1 FY26 at ₹88.6 cr vs negative ₹44 cr in H1 FY25 |
| CDMO revenue | ₹509 cr, degrowth vs Q2 FY25; H1 flat YoY; second half expected stronger |
| CDMO EBITDA margin | 25.3%, vs 19% in Q2 FY25; driven by late Phase 3 and ADC supplies to Japanese innovator |
| Marketable Molecules revenue | ₹143 cr, 85% growth vs Q2 FY25; H1 at ₹240 cr, 33.7% growth |
| Marketable Molecules EBITDA margin | 14%, vs 15.7% in Q2 FY25; Naroda/Quats margins lower; cholesterol and vitamin D analogues at ~18% margin |
| Revenue growth guidance FY26 | 8% to 10% total revenue growth expected |
| EBITDA margin guidance FY26 | ~20%, up from earlier guided 18%–20% |
| CDMO revenue target FY27 | ₹3,000 cr targeted |
| Net debt | CHF 14.1 cr, vs CHF 15.7 cr as of March 31, 2025 |
| CapEx | $7.3 mn in Q2; $13 mn in H1; full year guidance ₹200–210 cr |
| Bavla site utilization | 20% to 25% currently; revenue target of ₹800 cr over next three years |
| French facility EBITDA breakeven | €18 mn revenue; peak potential €45 mn at ~35% EBITDA margin |
| Development pipeline (Carbogen Amcis) | CHF 15 cr as of September 30, 2025 |
| Commercial order book (Carbogen Amcis) | CHF 10 cr as of September 30, 2025 |
| ROCE target | 25% over next 4–5 years |